Abstract

BackgroundThe lungworm Dictyocaulus viviparus, causing parasitic bronchitis in cattle, induces a temporary protective immunity that prevents clinical disease. A radiation-attenuated larvae based vaccine is commercially available in a few European countries, but has the disadvantages of a live vaccine. As a recombinant subunit vaccine would overcome these disadvantages, the parasite’s muscle protein paramyosin (PMY) was tested as a recombinant vaccine antigen.MethodsD. viviparus-PMY was recombinantly expressed in Escherichia coli as a glutathione-S-transferase (GST)-fused protein. Emulsified in adjuvant Saponin Quil A, the protein was given intramuscularly into calves. Two independent recombinant PMY (rPMY) vaccination trials with negative control groups (first trial: adjuvant only; second trial: non-fused GST) as well as an additional positive control group in the second trial, using the Bovilis©Dictol live vaccine to verify vaccination results, were performed. To determine the vaccination success, shedding of larvae as well as worm burden and worm sizes were analyzed. Additionally, ELISA-based determination of development of immunglobulins IgM, IgA, IgE, IgG as well as the subclasses IgG1 and IgG2 was performed. To analyze PMY localization in the bovine lungworm, immunohistochemical staining of adult worms was carried out.ResultsImmunohistochemical staining revealed that PMY is part of the bovine lungworm’s pharyngeal and body wall muscles. Vaccination with rPMY resulted in 47% [geometric mean: 67%] and 57% (geometric mean: 71%) reduction of larvae shedding in the first and second vaccination trial, respectively. Worm burden was reduced by 54% (geometric mean: 86%) and 31% (geometric mean: 68%), respectively, and worms of rPMY-vaccinated cattle were significantly shorter in both trials. Furthermore, ELISAs showed a clear antibody response towards rPMY with exception of IgE for which titers could not be detected. After challenge infection, rPMY antibodies were only exceptionally elevated among study animals indicating PMY to be a hidden antigen.ConclusionsEven though vaccination with the attenuated live vaccine was with 94% (geometric mean: 95%) reduction in larvae shedding and 93% (geometric mean: 94%) reduction in worm burden superior to rPMY vaccination, results using the latter are promising and show the potential for further development of a recombinant PMY-based vaccine against the bovine lungworm.

Highlights

  • The lungworm Dictyocaulus viviparus, causing parasitic bronchitis in cattle, induces a temporary protective immunity that prevents clinical disease

  • Even though vaccination with the attenuated live vaccine was with 94% reduction in larvae shedding and 93% reduction in worm burden superior to rPMY vaccination, results using the latter are promising and show the potential for further development of a recombinant PMY-based vaccine against the bovine lungworm

  • The present study aimed to evaluate the potential of the antigen paramyosin as a recombinant subunit vaccine against the bovine lungworm in clinical vaccine trials

Read more

Summary

Introduction

The lungworm Dictyocaulus viviparus, causing parasitic bronchitis in cattle, induces a temporary protective immunity that prevents clinical disease. Bovine lungworm-PMY might have immunomodulatory functions protecting against host defense mechanisms, making it a potential vaccine target to control parasitic bronchitis. This assumption is substantiated by promising rPMY vaccination trials against trematodes like Schistosoma spp. and Fasciola gigantica [14,15,16]. Vaccination trials in large animal hosts like cattle, sheep or pigs with recombinant S. japonicum-PMY resulted in a partial protection against challenge infections: After immunization of pigs, 32-35% reduction of worm burden was observed [17]. The above results suggest PMY as a valuable helminth vaccine candidate why its protective potential against the bovine lungworm D. viviparus was evaluated in the present study

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call